Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
6 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies.
Clin Cancer Res. 2021 Apr 15;27(8):2190-2199. doi: 10.1158/1078-0432.CCR-20-3706. Epub 2021 Jan 15.
Clin Cancer Res. 2021.
PMID: 33451977
Clinical Trial.
TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding.
Petrova PS, Viller NN, Wong M, Pang X, Lin GH, Dodge K, Chai V, Chen H, Lee V, House V, Vigo NT, Jin D, Mutukura T, Charbonneau M, Truong T, Viau S, Johnson LD, Linderoth E, Sievers EL, Maleki Vareki S, Figueredo R, Pampillo M, Koropatnick J, Trudel S, Mbong N, Jin L, Wang JC, Uger RA.
Petrova PS, et al.
Clin Cancer Res. 2017 Feb 15;23(4):1068-1079. doi: 10.1158/1078-0432.CCR-16-1700. Epub 2016 Nov 17.
Clin Cancer Res. 2017.
PMID: 27856600
Item in Clipboard
Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study.
Querfeld C, Thompson JA, Taylor MH, DeSimone JA, Zain JM, Shustov AR, Johns C, McCann S, Lin GHY, Petrova PS, Uger RA, Molloy N, Shou Y, Akilov OE.
Querfeld C, et al. Among authors: petrova ps.
Lancet Haematol. 2021 Nov;8(11):e808-e817. doi: 10.1016/S2352-3026(21)00271-4. Epub 2021 Oct 7.
Lancet Haematol. 2021.
PMID: 34627593
Clinical Trial.
Item in Clipboard
TTI-621 (SIRPαFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets.
Lin GHY, Chai V, Lee V, Dodge K, Truong T, Wong M, Johnson LD, Linderoth E, Pang X, Winston J, Petrova PS, Uger RA, Viller NN.
Lin GHY, et al. Among authors: petrova ps.
PLoS One. 2017 Oct 30;12(10):e0187262. doi: 10.1371/journal.pone.0187262. eCollection 2017.
PLoS One. 2017.
PMID: 29084248
Free PMC article.
Item in Clipboard
Discovering novel phenotype-selective neurotrophic factors to treat neurodegenerative diseases.
Petrova PS, Raibekas A, Pevsner J, Vigo N, Anafi M, Moore MK, Peaire A, Shridhar V, Smith DI, Kelly J, Durocher Y, Commissiong JW.
Petrova PS, et al.
Prog Brain Res. 2004;146:168-83. doi: 10.1016/s0079-6123(03)46012-3.
Prog Brain Res. 2004.
PMID: 14699964
Review.
Item in Clipboard
MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons.
Petrova P, Raibekas A, Pevsner J, Vigo N, Anafi M, Moore MK, Peaire AE, Shridhar V, Smith DI, Kelly J, Durocher Y, Commissiong JW.
Petrova P, et al.
J Mol Neurosci. 2003 Apr;20(2):173-88. doi: 10.1385/jmn:20:2:173.
J Mol Neurosci. 2003.
PMID: 12794311
Item in Clipboard
Cite
Cite